Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Title Ibritumomab tiuxetan FDA Drug Label
Abstract Text


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Ibritumomab tiuxetan Ibritumomab tiuxetan 1 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
Ibritumomab tiuxetan Zevalin IDEC Y2B8 CD20 Antibody 11 Zevalin (britumomab tiuxetan) is Yttrium-90 combined with the anti-CD20 antibody, rituximab, which may deliver radiation to tumor cells (PMID: 27497027). Zevalin (britumomab tiuxetan) is FDA approved for use in patients with low-grade or follicular B-cell non-Hodgkin's lymphoma (
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown non-Hodgkin lymphoma not applicable Ibritumomab tiuxetan FDA approved Actionable In a Phase I trial that supported FDA approval, Zevalin (ibritumomab tiuxetan) treatment resulted in significantly improved objective response rate (83% vs 55%, p<0.001) compared to Rituxan (rituximab) in patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (PMID: 27497027). 27497027 detail...